MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis.
BioMS Medical Corp, under license from the University of Alberta, is developing MBP-8298, a synthetic peptide analog of myelin basic protein, for the potential treatment of multiple sclerosis. Phase II and III clinical trials of MBP-8298 are underway.